MorphoSys and Schering-Plough sign r&d deal
MorphoSys has granted Schering-Plough an initial two-year licensing agreement for the use of the HuCAL GOLD antibody library in its r&d of human therapeutic antibodies.
MorphoSys has granted Schering-Plough an initial two-year licensing agreement for the use of the HuCAL GOLD antibody library in its r&d of human therapeutic antibodies.
Under the terms of the agreement, the HuCAL GOLD library will be installed at Schering-Ploguh's research site in Palo Alto, California, US, - also the site of the company's affiliate, Schering-Plough Biopharma - for use in its drug discovery programmes. The company will also have the option to develop HuCAL-derived therapeutic antibodies against up to 10 disease-related targets and to extend the agreement for up to three years
On top of an upfront payment, annual user fees and optional r&d funding, MorphoSys will be eligible to receive license and milestone payments related to the success of projects in clinical development and royalties on HuCAL antibodies developed under the agreement.
"This agreement is our twelfth with a top 20 pharmaceutical company [and] marks further progress in the successful execution of our strategy to strengthen the pipeline of therapeutic antibodies based on our proprietary technology through strategic deals," said Dr Simon Moroney, ceo MorphoSys.